PACB
Price
$1.64
Change
+$0.04 (+2.50%)
Updated
Jan 17 closing price
Capitalization
976.68M
25 days until earnings call
VCYT
Price
$40.58
Change
-$0.52 (-1.27%)
Updated
Jan 17 closing price
Capitalization
1.66B
44 days until earnings call
Ad is loading...

PACB vs VCYT

Header iconPACB vs VCYT Comparison
Open Charts PACB vs VCYTBanner chart's image
Pacific Biosciences of California
Price$1.64
Change+$0.04 (+2.50%)
Volume$6.64M
Capitalization976.68M
Veracyte
Price$40.58
Change-$0.52 (-1.27%)
Volume$2.57M
Capitalization1.66B
PACB vs VCYT Comparison Chart
Loading...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCYT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PACB vs. VCYT commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PACB is a Hold and VCYT is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (PACB: $1.64 vs. VCYT: $40.58)
Brand notoriety: PACB and VCYT are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: PACB: 69% vs. VCYT: 321%
Market capitalization -- PACB: $976.68M vs. VCYT: $1.66B
PACB [@Medical Specialties] is valued at $976.68M. VCYT’s [@Medical Specialties] market capitalization is $1.66B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PACB’s FA Score shows that 0 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).

  • PACB’s FA Score: 0 green, 5 red.
  • VCYT’s FA Score: 0 green, 5 red.
According to our system of comparison, VCYT is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PACB’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 3 bullish TA indicator(s).

  • PACB’s TA Score: 4 bullish, 4 bearish.
  • VCYT’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, VCYT is a better buy in the short-term than PACB.

Price Growth

PACB (@Medical Specialties) experienced а -21.90% price change this week, while VCYT (@Medical Specialties) price change was -2.31% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.97%. For the same industry, the average monthly price growth was +5.53%, and the average quarterly price growth was +1.10%.

Reported Earning Dates

PACB is expected to report earnings on May 01, 2025.

VCYT is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Medical Specialties (+0.97% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VCYT($1.66B) has a higher market cap than PACB($977M). VCYT YTD gains are higher at: 2.475 vs. PACB (-10.383). VCYT has higher annual earnings (EBITDA): -49.41M vs. PACB (-277.28M). PACB has more cash in the bank: 631M vs. VCYT (216M). VCYT has less debt than PACB: VCYT (12.6M) vs PACB (934M). VCYT has higher revenues than PACB: VCYT (361M) vs PACB (201M).
PACBVCYTPACB / VCYT
Capitalization977M1.66B59%
EBITDA-277.28M-49.41M561%
Gain YTD-10.3832.475-420%
P/E RatioN/AN/A-
Revenue201M361M56%
Total Cash631M216M292%
Total Debt934M12.6M7,413%
FUNDAMENTALS RATINGS
PACB vs VCYT: Fundamental Ratings
PACB
VCYT
OUTLOOK RATING
1..100
7261
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
10078
SMR RATING
1..100
9890
PRICE GROWTH RATING
1..100
8738
P/E GROWTH RATING
1..100
81100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VCYT's Valuation (39) in the Biotechnology industry is somewhat better than the same rating for PACB (99). This means that VCYT’s stock grew somewhat faster than PACB’s over the last 12 months.

VCYT's Profit vs Risk Rating (78) in the Biotechnology industry is in the same range as PACB (100). This means that VCYT’s stock grew similarly to PACB’s over the last 12 months.

VCYT's SMR Rating (90) in the Biotechnology industry is in the same range as PACB (98). This means that VCYT’s stock grew similarly to PACB’s over the last 12 months.

VCYT's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for PACB (87). This means that VCYT’s stock grew somewhat faster than PACB’s over the last 12 months.

PACB's P/E Growth Rating (81) in the Biotechnology industry is in the same range as VCYT (100). This means that PACB’s stock grew similarly to VCYT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PACBVCYT
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 11 days ago
89%
Momentum
ODDS (%)
Bullish Trend 11 days ago
87%
Bullish Trend 11 days ago
87%
MACD
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 11 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 11 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
86%
Bullish Trend 11 days ago
83%
Advances
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 13 days ago
76%
Declines
ODDS (%)
Bearish Trend 20 days ago
88%
Bearish Trend 19 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCYT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VFTNX41.310.44
+1.08%
Vanguard FTSE Social Index I
ATYGX12.390.05
+0.41%
American Century International Gr Y
RGYTX9.350.03
+0.32%
Russell Inv Multi-Strategy Income M
BUFIX21.100.05
+0.24%
Buffalo International
LPERX4.51N/A
N/A
ALPS Global Opportunity R

VCYT and

Correlation & Price change

A.I.dvisor indicates that over the last year, VCYT has been closely correlated with NTLA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if VCYT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VCYT
1D Price
Change %
VCYT100%
-1.27%
NTLA - VCYT
69%
Closely correlated
+0.85%
VCEL - VCYT
60%
Loosely correlated
+4.83%
AXON - VCYT
58%
Loosely correlated
+1.37%
DNA - VCYT
57%
Loosely correlated
+6.18%
ABCL - VCYT
55%
Loosely correlated
+1.02%
More